NextBillion - An Initiative of the William Davidson Institute at the University of Michigan

Aisling Capital, a late-stage life sciences investment firm that partners with companies to successfully bring novel medical therapies to market, today announced the closing of its newest fund, with $280 million in committed capital.  The capital raised will allow Aisling Capital to continue helping clinical stage ventures improve global health by more rapidly bringing breakthrough medical treatments to market.

Aisling Capital will assist companies developing therapeutics to complete their clinical studies, navigate approval and ultimately reach commercialization. Portfolio companies gain access to Aisling Capital’s strategic counsel and deep experience in both financial and medical fields, along with its unmatched network that extends from regulatory organizations to leading pharmaceutical companies and financial institutions. Aisling Capital is determined to increase the number of quality medical therapeutics in development and get treatments into the hands of people who need it.

Photo courtesy of psyberartist.